cefalexin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 571 15686-71-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefalexin hydrochloride
  • cephalexin
  • cefalexin
  • cephacillin
  • cephalexin anhydrous
  • cephalexin hydrochloride
  • cephalexin hydrate
  • cefalexin HCl
  • cephalexin HCl
A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.
  • Molecular weight: 347.39
  • Formula: C16H17N3O4S
  • CLOGP: -1.84
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 3
  • TPSA: 112.73
  • ALOGS: -3.07
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 12 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 91 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 192.00 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.21 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.57 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 4, 1971 FDA SHIONOGI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1091.81 10.87 1064 32370 249946 50321744
Cross sensitivity reaction 218.36 10.87 72 33362 1897 50569793
Type IV hypersensitivity reaction 209.62 10.87 74 33360 2408 50569282
Cellulitis 95.09 10.87 169 33265 70629 50501061
Loss of employment 85.37 10.87 34 33400 1552 50570138
Drug ineffective 82.53 10.87 273 33161 819060 49752630
Rash maculo-papular 68.10 10.87 86 33348 26555 50545135
Pemphigus 66.65 10.87 3 33431 120163 50451527
Synovitis 65.85 10.87 4 33430 123861 50447829
Injury 64.65 10.87 116 33318 48809 50522881
Urinary tract infection 58.90 10.87 298 33136 223722 50347968
Oesophageal spasm 58.10 10.87 29 33405 2267 50569423
Systemic lupus erythematosus 54.44 10.87 13 33421 140609 50431081
Hand deformity 53.98 10.87 3 33431 100196 50471494
Infusion related reaction 51.16 10.87 24 33410 169533 50402157
Glossodynia 50.38 10.87 8 33426 115561 50456129
Oesophageal pain 47.22 10.87 27 33407 2775 50568915
Joint swelling 44.62 10.87 58 33376 245228 50326462
Emotional distress 44.48 10.87 73 33361 28590 50543100
Pericarditis 40.47 10.87 3 33431 78686 50493004
Toxicity to various agents 39.94 10.87 49 33385 212450 50359240
Arthropathy 38.29 10.87 29 33405 157877 50413813
Lymphoedema 38.01 10.87 38 33396 9084 50562606
Urinary tract discomfort 36.02 10.87 11 33423 224 50571466
Rash 36.00 10.87 444 32990 437027 50134663
Cholecystitis chronic 34.39 10.87 37 33397 9632 50562058
Acute generalised exanthematous pustulosis 33.20 10.87 35 33399 8903 50562787
Completed suicide 32.25 10.87 24 33410 131865 50439825
Cystitis 31.47 10.87 82 33352 44482 50527208
Oedema 31.46 10.87 110 33324 70071 50501619
Chronic kidney disease 29.97 10.87 75 33359 39696 50531994
Uterine perforation 29.11 10.87 28 33406 6387 50565303
Alveolar osteitis 29.09 10.87 11 33423 436 50571254
Treatment failure 28.85 10.87 29 33405 137608 50434082
Bronchomalacia 28.20 10.87 9 33425 213 50571477
Hepatic enzyme increased 27.61 10.87 30 33404 137350 50434340
Rheumatoid arthritis 26.59 10.87 59 33375 202491 50369199
Deep vein thrombosis 26.30 10.87 107 33327 73197 50498493
Hepatitis infectious mononucleosis 26.29 10.87 7 33427 85 50571605
Pigment nephropathy 26.15 10.87 6 33428 37 50571653
Intentional overdose 25.76 10.87 5 33429 62499 50509191
Anxiety 25.72 10.87 203 33231 177403 50394287
Limb injury 25.45 10.87 47 33387 20203 50551487
Urticaria 25.14 10.87 159 33275 129402 50442288
Animal scratch 24.57 10.87 12 33422 895 50570795
Alopecia 24.21 10.87 82 33352 244965 50326725
Tunnel vision 24.04 10.87 11 33423 708 50570982
Depression 23.91 10.87 189 33245 165234 50406456
Bronchitis 23.51 10.87 133 33301 104026 50467664
Familial periodic paralysis 23.50 10.87 6 33428 61 50571629
Bladder pain 22.72 10.87 14 33420 1650 50570040
General physical health deterioration 22.61 10.87 37 33397 142397 50429293
Contraindicated product administered 22.45 10.87 40 33394 148918 50422772
Hallucination 21.66 10.87 74 33360 46583 50525107
Hepatic steatosis 21.63 10.87 49 33385 24335 50547355
Agitation neonatal 21.02 10.87 9 33425 494 50571196
Toxic epidermal necrolysis 20.68 10.87 44 33390 20948 50550742
Gallbladder disorder 19.97 10.87 38 33396 16704 50554986
Poor feeding infant 19.56 10.87 7 33427 237 50571453
Therapeutic product effect incomplete 19.49 10.87 19 33415 91496 50480194
Drug intolerance 19.22 10.87 77 33357 219027 50352663
Off label use 19.10 10.87 211 33223 474215 50097475
Amniotic cavity infection 19.05 10.87 11 33423 1152 50570538
Bronchopulmonary aspergillosis allergic 18.80 10.87 11 33423 1180 50570510
Wound complication 18.48 10.87 15 33419 2735 50568955
Implant site haematoma 17.86 10.87 5 33429 74 50571616
Immunoglobulins decreased 17.74 10.87 10 33424 1000 50570690
Overdose 17.68 10.87 24 33410 99703 50471987
Diarrhoea 17.14 10.87 509 32925 587967 49983723
Nephrolithiasis 16.96 10.87 56 33378 34637 50537053
Sleep apnoea syndrome 16.93 10.87 44 33390 23824 50547866
Dysuria 16.70 10.87 49 33385 28455 50543235
Gastric disorder 16.56 10.87 50 33384 29498 50542192
Intentional product use issue 16.35 10.87 16 33418 76902 50494788
Migraine 16.25 10.87 95 33339 75185 50496505
Staphylococcal infection 16.10 10.87 56 33378 35560 50536130
Type I hypersensitivity 16.01 10.87 13 33421 2372 50569318
Vanishing bile duct syndrome 15.98 10.87 8 33426 629 50571061
Paranasal sinus discomfort 15.41 10.87 14 33420 2972 50568718
Abscess drainage 15.28 10.87 7 33427 452 50571238
Nasal polyps 15.23 10.87 13 33421 2541 50569149
Product dose omission issue 15.22 10.87 187 33247 183651 50388039
Complement factor C4 increased 15.15 10.87 5 33429 132 50571558
Pruritus 15.04 10.87 267 33167 283301 50288389
Polymyalgia rheumatica 14.88 10.87 13 33421 2623 50569067
Foetal heart rate decreased 14.80 10.87 5 33429 142 50571548
Discomfort 14.68 10.87 31 33403 108349 50463341
Sinus pain 14.50 10.87 12 33422 2249 50569441
Appetite disorder 14.46 10.87 19 33415 6095 50565595
Multiple lentigines syndrome 14.45 10.87 5 33429 153 50571537
Anhedonia 14.43 10.87 24 33410 9500 50562190
Coma 14.35 10.87 10 33424 56869 50514821
Purpura senile 14.33 10.87 7 33427 522 50571168
Wound secretion 14.27 10.87 15 33419 3802 50567888
Morbid thoughts 14.17 10.87 7 33427 535 50571155
Therapy interrupted 14.14 10.87 37 33397 20115 50551575
Abdominal pain upper 14.04 10.87 164 33270 159145 50412545
Delirium 13.87 10.87 4 33430 38188 50533502
Hidradenitis 13.76 10.87 11 33423 1964 50569726
Ear congestion 13.62 10.87 11 33423 1992 50569698
Skin infection 13.57 10.87 27 33407 12264 50559426
Ureteric obstruction 13.37 10.87 10 33424 1618 50570072
Umbilical cord around neck 13.35 10.87 5 33429 193 50571497
Skin cancer 13.34 10.87 23 33411 9371 50562319
Cholelithiasis 13.27 10.87 55 33379 37918 50533772
Liposuction 13.14 10.87 3 33431 18 50571672
Developmental hip dysplasia 13.06 10.87 9 33425 1282 50570408
Clostridium difficile colitis 12.89 10.87 33 33401 17709 50553981
Retroperitoneal haematoma 12.88 10.87 12 33422 2631 50569059
Therapy cessation 12.73 10.87 42 33392 25969 50545721
Arthritis infective 12.70 10.87 17 33417 5552 50566138
Procedural pain 12.50 10.87 28 33406 13804 50557886
Clostridium difficile infection 12.38 10.87 41 33393 25398 50546292
Genital ulceration 12.29 10.87 6 33428 447 50571243
Loss of personal independence in daily activities 12.27 10.87 17 33417 70033 50501657
Meconium in amniotic fluid 12.22 10.87 5 33429 245 50571445
Ecthyma 12.18 10.87 5 33429 247 50571443
Anaphylactic reaction 12.17 10.87 69 33365 53986 50517704
Drug abuse 12.09 10.87 13 33421 59833 50511857
Helicobacter duodenal ulcer 12.08 10.87 3 33431 27 50571663
Bronchiectasis 11.85 10.87 23 33411 10260 50561430
Muscle haemorrhage 11.73 10.87 12 33422 2946 50568744
Skin laceration 11.63 10.87 33 33401 18809 50552881
Vertigo positional 11.47 10.87 11 33423 2500 50569190
Malignant neoplasm progression 11.47 10.87 17 33417 68107 50503583
Tarsal tunnel syndrome 11.30 10.87 6 33428 533 50571157
Swelling 11.27 10.87 82 33352 200790 50370900
Rhabdomyolysis 11.04 10.87 6 33428 39021 50532669
Diabetic retinal oedema 10.94 10.87 5 33429 321 50571369

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 140.21 13.10 172 14663 68234 29491458
Cellulitis 83.86 13.10 109 14726 45731 29513961
Rash 69.57 13.10 231 14604 189588 29370104
Clostridium test positive 39.79 13.10 20 14815 2097 29557595
Pruritus 37.29 13.10 136 14699 116713 29442979
Drug tolerance decreased 32.20 13.10 15 14820 1331 29558361
Clostridium difficile infection 32.03 13.10 40 14795 16101 29543591
Localised infection 31.94 13.10 37 14798 13779 29545913
Venolymphatic malformation 30.15 13.10 6 14829 23 29559669
Drug interaction 29.90 13.10 33 14802 197352 29362340
Drug abuse 29.34 13.10 3 14832 79880 29479812
Urinary tract infection 29.04 13.10 91 14744 72263 29487429
Skin infection 27.10 13.10 24 14811 6503 29553189
Urticaria 26.96 13.10 74 14761 54586 29505106
Circumoral oedema 26.66 13.10 6 14829 46 29559646
Renal hypoplasia 25.14 13.10 6 14829 61 29559631
Limb injury 24.96 13.10 27 14808 9328 29550364
Erythema 24.93 13.10 89 14746 75517 29484175
Rash pruritic 24.70 13.10 42 14793 22321 29537371
Joint swelling 24.29 13.10 67 14768 49563 29510129
Cross sensitivity reaction 23.94 13.10 12 14823 1250 29558442
Gut fermentation syndrome 22.73 13.10 4 14831 6 29559686
Kounis syndrome 22.39 13.10 13 14822 1816 29557876
Biliary sepsis 22.18 13.10 9 14826 571 29559121
Type IV hypersensitivity reaction 21.79 13.10 11 14824 1163 29558529
Skin laceration 21.29 13.10 27 14808 11035 29548657
Stevens-Johnson syndrome 20.94 13.10 33 14802 16464 29543228
Toxicity to various agents 19.39 13.10 36 14799 173625 29386067
Haemorrhoids thrombosed 18.80 13.10 6 14829 189 29559503
Therapy interrupted 18.61 13.10 22 14813 8364 29551328
Alveolar osteitis 18.47 13.10 5 14830 87 29559605
Allergy test positive 18.22 13.10 4 14831 27 29559665
Arthropathy 18.14 13.10 36 14799 21518 29538174
Perineal abscess 18.09 13.10 6 14829 214 29559478
Skin necrosis 18.01 13.10 17 14818 4995 29554697
Peripheral swelling 17.67 13.10 71 14764 63668 29496024
Swollen tongue 17.64 13.10 26 14809 12240 29547452
Mucormycosis 17.60 13.10 17 14818 5141 29554551
Retinal degeneration 17.36 13.10 7 14828 437 29559255
Urinary tract discomfort 17.33 13.10 5 14830 111 29559581
Treatment failure 17.21 13.10 49 14786 36890 29522802
Polyomavirus-associated nephropathy 17.20 13.10 14 14821 3382 29556310
General physical health deterioration 16.90 13.10 16 14819 102841 29456851
Lip haemorrhage 16.89 13.10 8 14827 737 29558955
Fungal skin infection 16.81 13.10 12 14823 2386 29557306
Renal injury 16.69 13.10 23 14812 10179 29549513
Neovascular age-related macular degeneration 16.58 13.10 5 14830 130 29559562
Skin ulcer 16.50 13.10 32 14803 18808 29540884
Clostridium difficile colitis 16.18 13.10 26 14809 13186 29546506
Multiple allergies 15.85 13.10 11 14824 2091 29557601
Middle ear effusion 15.73 13.10 7 14828 558 29559134
Skin lesion 15.60 13.10 31 14804 18541 29541151
Hypersensitivity vasculitis 15.60 13.10 13 14822 3244 29556448
Angioedema 15.52 13.10 43 14792 31872 29527820
Factor V inhibition 15.36 13.10 5 14830 168 29559524
Animal scratch 14.79 13.10 5 14830 189 29559503
Renal tubular necrosis 14.65 13.10 26 14809 14289 29545403
Herpes simplex 14.62 13.10 15 14820 4875 29554817
Urethral injury 14.40 13.10 4 14831 77 29559615
Tubulointerstitial nephritis 14.28 13.10 29 14806 17614 29542078
Pyogenic granuloma 14.03 13.10 5 14830 222 29559470
Mean platelet volume increased 14.03 13.10 6 14829 435 29559257
Skin cancer 13.72 13.10 19 14816 8449 29551243
Arthritis 13.46 13.10 35 14800 24984 29534708
Rheumatoid factor negative 13.17 13.10 7 14828 823 29558869

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 819.31 10.85 857 38351 236958 64222566
Type IV hypersensitivity reaction 232.53 10.85 85 39123 3337 64456187
Cross sensitivity reaction 230.16 10.85 84 39124 3283 64456241
Cellulitis 145.65 10.85 228 38980 93429 64366095
Rash 96.71 10.85 540 38668 458009 64001515
Loss of employment 78.68 10.85 33 39175 1874 64457650
Urinary tract infection 63.57 10.85 294 38914 231302 64228222
Rash maculo-papular 62.89 10.85 107 39101 46919 64412605
Oesophageal spasm 60.73 10.85 30 39178 2495 64457029
Toxicity to various agents 57.93 10.85 82 39126 363431 64096093
Oesophageal pain 56.22 10.85 31 39177 3232 64456292
Injury 53.15 10.85 110 39098 55882 64403642
Urticaria 48.81 10.85 198 39010 147119 64312405
Pruritus 47.63 10.85 339 38869 312061 64147463
Drug abuse 45.69 10.85 12 39196 132362 64327162
Urinary tract discomfort 45.15 10.85 14 39194 328 64459196
Synovitis 42.83 10.85 5 39203 99085 64360439
Oedema 42.72 10.85 138 39070 91797 64367727
Alveolar osteitis 42.25 10.85 14 39194 408 64459116
Limb injury 41.85 10.85 61 39147 23444 64436080
Emotional distress 39.24 10.85 75 39133 35963 64423561
Clostridium difficile infection 39.06 10.85 75 39133 36088 64423436
Drug ineffective 38.83 10.85 326 38882 839921 63619603
Lymphoedema 38.04 10.85 38 39170 9867 64449657
Infusion related reaction 36.41 10.85 28 39180 164439 64295085
Clostridium test positive 35.06 10.85 25 39183 4090 64455434
Acute generalised exanthematous pustulosis 35.04 10.85 43 39165 14015 64445509
Cholecystitis chronic 34.51 10.85 35 39173 9252 64450272
Animal scratch 33.80 10.85 15 39193 978 64458546
Uterine perforation 33.47 10.85 28 39180 5792 64453732
Completed suicide 33.40 10.85 53 39155 224361 64235163
Skin infection 32.74 10.85 43 39165 14994 64444530
General physical health deterioration 31.65 10.85 47 39161 204378 64255146
Bronchitis 31.23 10.85 140 39068 108603 64350921
Bladder pain 30.90 10.85 17 39191 1764 64457760
Cystitis 30.60 10.85 75 39133 42600 64416924
Tunnel vision 29.68 10.85 14 39194 1051 64458473
Drug interaction 28.05 10.85 119 39089 361964 64097560
Pericarditis 27.40 10.85 3 39205 62513 64397011
Deep vein thrombosis 26.96 10.85 131 39077 105051 64354473
Lactic acidosis 26.78 10.85 3 39205 61407 64398117
Pigment nephropathy 25.86 10.85 6 39202 43 64459481
Chronic kidney disease 25.16 10.85 85 39123 57834 64401690
Hand deformity 25.15 10.85 4 39204 62767 64396757
Skin laceration 24.38 10.85 49 39159 24368 64435156
Hepatitis infectious mononucleosis 24.21 10.85 7 39201 128 64459396
Bronchopulmonary aspergillosis allergic 24.13 10.85 14 39194 1608 64457916
Pemphigus 24.03 10.85 4 39204 60697 64398827
Migraine 23.80 10.85 88 39120 62589 64396935
Off label use 23.43 10.85 259 38949 632547 63826977
Gallbladder disorder 23.09 10.85 39 39169 16991 64442533
Genital ulceration 22.81 10.85 10 39198 633 64458891
Anxiety 22.68 10.85 205 39003 202444 64257080
Stevens-Johnson syndrome 22.26 10.85 58 39150 34191 64425333
Paranasal sinus discomfort 22.02 10.85 17 39191 3138 64456386
Nasal polyps 21.99 10.85 18 39190 3611 64455913
Gut fermentation syndrome 21.96 10.85 4 39204 6 64459518
Hepatic function abnormal 21.86 10.85 6 39202 64307 64395217
Wound secretion 21.82 10.85 21 39187 5211 64454313
Intentional overdose 21.62 10.85 14 39194 89930 64369594
Pemphigoid 20.69 10.85 32 39176 12954 64446570
Wound complication 20.67 10.85 18 39190 3930 64455594
Ear congestion 20.51 10.85 14 39194 2136 64457388
Sinus pain 20.39 10.85 15 39193 2574 64456950
Erythema 20.30 10.85 188 39020 186882 64272642
Systemic lupus erythematosus 20.18 10.85 11 39197 77601 64381923
Type I hypersensitivity 20.15 10.85 17 39191 3557 64455967
Sleep apnoea syndrome 19.88 10.85 51 39157 29781 64429743
Clostridium difficile colitis 19.68 10.85 48 39160 27175 64432349
Drug reaction with eosinophilia and systemic symptoms 19.65 10.85 75 39133 54142 64405382
Polymyalgia rheumatica 18.98 10.85 16 39192 3343 64456181
Therapeutic product effect incomplete 18.89 10.85 21 39187 103461 64356063
Familial periodic paralysis 18.87 10.85 6 39202 153 64459371
Depression 18.79 10.85 182 39026 183109 64276415
Implant site haematoma 18.76 10.85 6 39202 156 64459368
Rhabdomyolysis 18.59 10.85 17 39191 91709 64367815
Thrombocytopenia 18.28 10.85 72 39136 223729 64235795
Coma 18.04 10.85 16 39192 87599 64371925
Anaphylactic reaction 17.93 10.85 86 39122 68578 64390946
Febrile neutropenia 17.57 10.85 57 39151 187600 64271924
Product odour abnormal 17.28 10.85 10 39198 1143 64458381
Therapy cessation 17.15 10.85 51 39157 32438 64427086
Nephrolithiasis 17.14 10.85 62 39146 43621 64415903
Haemorrhoids thrombosed 17.09 10.85 6 39202 209 64459315
Skin cancer 17.01 10.85 28 39180 11946 64447578
Swollen tongue 16.70 10.85 53 39155 34901 64424623
Surgery 16.55 10.85 46 39162 28167 64431357
Localised infection 16.54 10.85 48 39160 30113 64429411
Toxic epidermal necrolysis 16.54 10.85 55 39153 37111 64422413
Diarrhoea 16.42 10.85 564 38644 722140 63737384
Kounis syndrome 16.26 10.85 14 39194 3011 64456513
Blister 16.06 10.85 94 39114 80873 64378651
Neutropenia 16.03 10.85 83 39125 239541 64219983
Lip swelling 15.82 10.85 49 39159 31858 64427666
Rash pruritic 15.80 10.85 73 39135 57331 64402193
Procedural pain 15.34 10.85 31 39177 15477 64444047
Oral pain 15.32 10.85 44 39164 27449 64432075
Complement factor C4 increased 15.28 10.85 5 39203 140 64459384
Circumoral oedema 15.24 10.85 6 39202 289 64459235
Tarsal tunnel syndrome 15.20 10.85 7 39201 498 64459026
Arthritis infective 15.14 10.85 20 39188 7010 64452514
Appetite disorder 14.88 10.85 19 39189 6442 64453082
Overdose 14.57 10.85 49 39159 159517 64300007
Skin ulcer 14.46 10.85 59 39149 43915 64415609
Middle ear effusion 14.45 10.85 11 39197 1988 64457536
Glossodynia 14.32 10.85 11 39197 64685 64394839
Diabetic retinal oedema 14.30 10.85 6 39202 341 64459183
Therapy interrupted 14.13 10.85 35 39173 20001 64439523
Agranulocytosis 14.10 10.85 3 39205 38226 64421298
Tubulointerstitial nephritis 13.99 10.85 46 39162 30863 64428661
Vanishing bile duct syndrome 13.83 10.85 9 39199 1268 64458256
Multiple lentigines syndrome 13.71 10.85 5 39203 195 64459329
Gastric disorder 13.70 10.85 44 39164 29153 64430371
Product dose omission issue 13.44 10.85 179 39029 194568 64264956
Actinic keratosis 13.20 10.85 16 39192 5149 64454375
Tinea infection 12.99 10.85 8 39200 1024 64458500
Hidradenitis 12.97 10.85 11 39197 2318 64457206
Biliary sepsis 12.92 10.85 9 39199 1419 64458105
Renal tubular necrosis 12.92 10.85 36 39172 22074 64437450
Ear pain 12.83 10.85 39 39169 25097 64434427
Intentional product use issue 12.82 10.85 24 39184 95340 64364184
Morbid thoughts 12.79 10.85 7 39201 719 64458805
Neovascular age-related macular degeneration 12.74 10.85 5 39203 239 64459285
Cholelithiasis 12.62 10.85 58 39150 45448 64414076
Ureteric obstruction 12.60 10.85 11 39197 2411 64457113
Lip haemorrhage 12.27 10.85 8 39200 1131 64458393
Polyomavirus-associated nephropathy 12.26 10.85 15 39193 4873 64454651
Bone marrow failure 12.17 10.85 7 39201 47945 64411579
Helicobacter duodenal ulcer 12.14 10.85 3 39205 29 64459495
Purpura senile 12.08 10.85 6 39202 505 64459019
Anaemia 12.06 10.85 160 39048 378520 64081004
Dysuria 11.95 10.85 54 39154 42003 64417521
Hepatic enzyme increased 11.79 10.85 40 39168 129903 64329621
Abscess drainage 11.77 10.85 6 39202 533 64458991
Pollakiuria 11.74 10.85 44 39164 31486 64428038
Blood creatine phosphokinase increased 11.69 10.85 11 39197 58547 64400977
Back pain 11.57 10.85 215 38993 249956 64209568
Malignant neoplasm progression 11.47 10.85 33 39175 112838 64346686
Tinnitus 11.38 10.85 46 39162 34087 64425437
Immune thrombocytopenia 11.35 10.85 27 39181 15039 64444485
Cardiogenic shock 11.07 10.85 3 39205 32424 64427100
Serotonin syndrome 11.07 10.85 5 39203 39277 64420247
Renal injury 10.93 10.85 27 39181 15402 64444122
Factor V inhibition 10.90 10.85 5 39203 352 64459172

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DB01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
CHEBI has role CHEBI:36047 antibacterial drugs
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute otitis media indication 3110003
Prostatitis indication 9713002 DOID:14654
Infection of skin AND/OR subcutaneous tissue indication 19824006
Pneumonia due to Streptococcus indication 34020007
Streptococcal tonsillitis indication 41582007
Klebsiella cystitis indication 60867007
Infection of bone indication 111253001
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Osteomyelitis due to Staphylococcus aureus indication 428783003
Klebsiella Prostatitis indication
Proteus Prostatitis indication
Haemophilus Influenzae Acute Otitis Media indication
Streptococcus Osteomyelitis indication
Staphylococcus Acute Otitis Media indication
Moraxella Catarrhalis Acute Otitis Media indication
Bacterial Mastitis off-label use
Prevention of Bacterial Endocarditis off-label use
Diabetic Foot Infection Due to Gram-Positive Bacteria off-label use
Colitis contraindication 64226004 DOID:0060180
Kidney disease contraindication 90708001 DOID:557
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Secondary superficial bacterial pyoderma caused by Staphylococcus pseudintermedius Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
Rilexine Chewable Tablets Virbac AH Inc. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.77 acidic
pKa2 13.53 acidic
pKa3 7.67 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 15 member 2 Transporter IC50 4.38 WOMBAT-PK
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 3 Enzyme WOMBAT-PK

External reference:

IDSource
4018893 VUID
N0000179741 NUI
D00263 KEGG_DRUG
23325-78-2 SECONDARY_CAS_RN
105879-42-3 SECONDARY_CAS_RN
1299782 RXNORM
4018891 VANDF
4018893 VANDF
C0007716 UMLSCUI
CHEBI:3534 CHEBI
CHEMBL1727 ChEMBL_ID
CHEMBL1200544 ChEMBL_ID
DB00567 DRUGBANK_ID
4832 IUPHAR_LIGAND_ID
OBN7UDS42Y UNII
27447 PUBCHEM_CID
4393 MMSL
d00096 MMSL
002716 NDDF
002717 NDDF
387304003 SNOMEDCT_US
54062005 SNOMEDCT_US
54887004 SNOMEDCT_US
785690001 SNOMEDCT_US
D002506 MESH_DESCRIPTOR_UI
CHEMBL1200366 ChEMBL_ID
2400 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-2238 TABLET 250 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-2238 TABLET 250 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-2240 TABLET 500 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-2240 TABLET 500 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-3145 CAPSULE 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-3145 CAPSULE 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-3147 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-3147 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-4175 POWDER, FOR SUSPENSION 125 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-4175 POWDER, FOR SUSPENSION 125 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-4177 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0093-4177 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9769 SUSPENSION 125 mg ORAL ANDA 24 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9770 SUSPENSION 250 mg ORAL ANDA 24 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9897 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9898 CAPSULE 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0440-1243 CAPSULE 250 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 0440-7244 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-004 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-013 CAPSULE 500 mg ORAL ANDA 24 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-020 CAPSULE 500 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-021 CAPSULE 250 mg ORAL ANDA 24 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-025 CAPSULE 500 mg ORAL ANDA 24 sections
cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-057 CAPSULE 500 mg ORAL ANDA 24 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-066 CAPSULE 250 mg ORAL ANDA 19 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-082 CAPSULE 500 mg ORAL ANDA 21 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-142 CAPSULE 250 mg ORAL ANDA 23 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-503 CAPSULE 500 mg ORAL ANDA 13 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-529 CAPSULE 500 mg ORAL ANDA 22 sections
Cephalexin HUMAN PRESCRIPTION DRUG LABEL 1 10544-617 CAPSULE 500 mg ORAL ANDA 19 sections